SAN DIEGO , Aug. 24, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces the appointment of Michael C. Dugan , M.D.
SAN DIEGO , Sept. 10, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the appointment of Edwin C.
SAN DIEGO --(BUSINESS WIRE)--Aug. 3, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed David Karlander as Senior Vice President of Commercial Operations. With more than 25 years of industry experience, Karlander will lead all
SAN DIEGO --(BUSINESS WIRE)--Feb. 10, 2022-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, has appointed Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer. With more than 30 years of healthcare experience,
Samuel D. Riccitelli resigns as interim President and CEO, and Director SAN DIEGO --(BUSINESS WIRE)--Jun. 20, 2023-- Biocept, Inc . (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, has named Antonino Morales as President and
Biocept Looking to Redefine CTC Dx Market, Plans Product Launch In the midst of a $5 million financing round, microfluidics company Biocept is looking to launch its first diagnostic test, as it embarks on “redefining what a circulating tumor cell is.” Thirteen years after its founding, and
SAN DIEGO , April 20, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of
First and only platform that enables local pathologists to obtain molecular biomarker information from a simple blood sample using cutting-edge circulating tumor cell (CTC) technology